Molecular basis of urinary bladder cancer

Advances in Anatomic Pathology

Volumn 20, Issue 1, 2013, Pages 53-60

  Al Hussain, Turki O ^a   Akhtar, Mohammed ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

bladder; carcinoma; fluorescent in situ hybridization; genes; molecular; mutations; plaque; preneoplastic; urothelium

Indexed keywords

BLADDER CANCER; CANCER GRADING; CANCER RECURRENCE; CARCINOGENESIS; CELL CYCLE; GENE DELETION; GENE MUTATION; HUMAN; MOLECULAR MECHANICS; PHENOTYPE; PRIORITY JOURNAL; REVIEW; STEM CELL; TRANSITIONAL CELL CARCINOMA;

CARCINOMA, PAPILLARY; HUMANS; NEOPLASMS, SECOND PRIMARY; PRECANCEROUS CONDITIONS; PROTO-ONCOGENE PROTEINS P21(RAS); RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; RETINOBLASTOMA PROTEIN; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

EID: 84871805906     PISSN: 10724109     EISSN: 15334031     Source Type: Journal    
DOI: 10.1097/PAP.0b013e31827bd0ec     Document Type: Review

References (48)

1. Sharma S, Ksheersagar P, Sharma P. Diagnosis and treatment of bladder cancer. Am Fam Physician. 2009;80:717-723.
2. Kaufman DS, William U, Shipley WU, et al. Bladder cancer. Lancet. 2009;374:239-249.
3. Gu J, Kiemeney L, Jemal A, et al. Cancer statistics. CA Cancer J Clin. 2010;60:277-300.
4. Anonymous. King Faisal Specialist Hospital and Research Center Tumor Registry Annual Report 2010. Riyadh, Saudi Arabia. December 2011.
5. Leppert JT, Shvarts O, Kelly Kawaoka K, et al. Prevention of bladder cancer: a review. Eur Urol. 2006;49:226-234. (Pubitemid 43197858)
6. Wu X, Ros MM, Gu J, et al. Epidemiology and genetic susceptibility to bladder cancer. BJU Int. 2008;102(9 Pt B): 1207-1215.
7. Sexton WJ,Wiegand LR, Correa JJ, et al. Bladder cancer: a review of non-muscle invasive disease. Cancer Control. 2010;17:256-268.
8. Letasiová S, Medved ová A,S ovc i'ková A, et al. Bladder cancer, a review of the environmental risk factors. Environ Health. 2012;11(suppl 1):S11.
9. Meliker JR, Nriagu JO. Arsenic in drinking water and bladder cancer: review of epidemiological evidence. Trace Metals and other Contaminants in the Environment. 2007;9:551-584. (Pubitemid 351734469)
10. Kuper H, Boffetta P, Adami HO. Tobacco use and cancer causation: association by tumour type. J Intern Med. 2002; 252:206-224.
11. ZeegersMPA, Kellen E, Buntinx F, et al. The association between smoking, beverage consumption, diet and bladder cancer: a systematic literature review. World J Urol. 2004;21:392-401.
12. Volanis D, Kadiyska T, Galanis A, et al. Environmental factors and genetic susceptibility promote urinary bladder cancer. Toxicol Lett. 2010;193:131-137.
13. .Mostafa MH, Sheweita SA, O'connor PJ. Relationship between schistosomiasis and bladder cancer. Clin Microbiol Rev. 1999;12:97-111. (Pubitemid 29055955)
14. Castillo-Martin M, Domingo-Domenech J, Karni-Schmidt O, et al. Molecular pathways of urothelial development and bladder tumorigenesis. Urol Oncol. 2010;28(4):401-408.
15. McConkey DJ, Lee S, Choi W, et al. Molecular genetics of bladder cancer: emerging mechanisms of tumor initiation and progression. Urol Oncol. 2010;28:429-440.
16. Nigwekar P, Amin MB. The many faces of urothelial carcinoma: an update with an emphasis on recently described variants. Adv Anat Pathol. 2008;15:218-233.
17. Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer. 1953;6:963-968.
18. Hong Chai, Brown RE. Field effect in cancer-an update. Ann Clin Lab Science. 2009;39:331-338.
19. Braakhuis BJM, Tabor MP, Kummer JA, et al. Genetic explanation of slaughter's concept of field cancerization: evidence and clinical implications. Cancer Res. 2003;63:1727-1730. (Pubitemid 36460827)
20. Dakubo GD, Jakupciak JP, Birch-Machin MA, et al. Clinical implications and utility of field cancerization. Cancer Cell Int. 2007;15;7:2.
21. Hoglund M. Bladder cancer, a two phased disease? Semin Cancer Biol. 2007;17:225-232. (Pubitemid 46413074)
22. Patrick C, Hermann PC, Bhaskar S, et al. Cancer stem cells in solid tumors. Semin Cancer Biol. 2010;20:77-84.
23. Houghton JM, Morozov A, Smirnova, Wang TC, et al. Stem cells and cancer Sem Cancer Biol. 2007;17:191-203. (Pubitemid 46415739)
24. Chan KS, Volkmer JP, Weissman I. Cancer stem cells in bladder cancer: a revisited and evolving concept. Curr Opin Urol. 2010;20:393-397.
25. Tran MN, Goodwin JG, McConkey DJ, et al. Bladder cancer stem cells. Curr Stem Cell Res Ther. 2010;5:387-395.
26. Brandt WD,MatsuiW, Rosenberg JE, et al. Urothelial carcinoma: stem cells on the edge. Cancer Metastasis Rev. 2009;28:291-304.
27. Tsai YC, Simoneau AR, Spruck CH 3rd, et al. Mosaicism in human epithelium: macroscopic monoclonal patches cover the urothelium. J Urol. 1995;153:1697-1700.
28. Sidransky D, Frost P, Von Eschenbach A, et al. Clonal origin bladder cancer. N Engl J Med. 1992;326:737-740.
29. Li M, Cannizzaro LA. Identical clonal origin of synchronous and metachronous low-grade, noninvasive papillary transitional cell carcinomas of the urinary tract. Hum Pathol. 1999;30: 1197-1200. (Pubitemid 29480888)
30. Hartmann A, Rosner U, Schlake G, et al. Clonality and genetic divergence in multifocal low-grade superficial urothelial carcinoma as determined by chromosome 9 and p53 deletion analysis. Lab Invest. 2000;80:709-718. (Pubitemid 30340655)
31. Dalbagni G, Ren ZP, Herr H, et al. Genetic alterations in tp53 in recurrent urothelial cancer: a longitudinal study. Clin Cancer Res. 2001;7:2797-7801.
32. Takahashi T, Habuchi T, Kakehi Y, et al. Clonal and chronological genetic analysis of multifocal cancers of the bladder and upper urinary tract. Cancer Res. 1998;58:5835-5841. (Pubitemid 29006426)
33. Hafner C, Knuechel R, Zanardo L, et al. Evidence for oligoclonality and tumor spread by intraluminal seeding in multifocal urothelial carcinomas of the upper and lower urinary tract. Oncogene. 2001;20:4910-4915. (Pubitemid 32803163)
34. Hartmann A, Schlake G, Zaak D, et al. Occurrence of chromosome 9 and p53 alterations in multifocal dysplasia and carcinoma in situ of human urinary bladder. Cancer Res. 2002;62:809-818. (Pubitemid 34126958)
35. Jones TD, Wang M, Eble JN, et al. Molecular evidence supporting field effect in urothelial carcinogenesis. Clin Cancer Res. 2005;11:6512-6519. (Pubitemid 41338989)
36. Czerniak B, Chaturvedi V, Li L, et al. Superimposed histologic and genetic mapping of chromosome 9 in progression of human urinary bladder neoplasia: implications for a genetic model of multistep urothelial carcinogenesis and early detection of urinary bladder cancer. Oncogene. 1999;18:1185-1196. (Pubitemid 29085991)
37. Pollard C, Smith SC, Theodorescu D. Molecular genesis of non-muscle-invasive urothelial carcinoma (NMIUC). Expert Rev Mol Med. 2010;12:e10.
38. Peter J, Goebell PJ, Knowles MA. Bladder cancer or bladder cancers? Genetically distinct malignant conditions of the urothelium. Urol Oncol. 2010;28:409-426.
39. Eswarakumar VP, Lax I, Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev. 2005;16:139-149. (Pubitemid 40616112)
40. L'Hô te CGM, Knowles MA. Cell responses to FGFR3 signalling: growth, differentiation and apoptosis. Exp Cell Res. 2005;304:417-443.
41. Nancy P, Caraway MD, Ruth L, et al. A review on the current state of urine cytology emphasizing the role of fluorescence in situ hybridization as an adjunct to diagnosis. Cancer Cytopathol. 2010;118:175-183.
42. He F, Mo L, Zheng XY, et al. Deficiency of pRb family proteins and p53 in invasive urothelial tumorigenesis. Cancer Res. 2009;69:9413-9421.
43. Zaak D, Karl A, Knu? chel R, et al. Diagnosis of urothelial carcinoma of the bladder using fluorescence endoscopy. BJU Int. 2005;96:217-222. (Pubitemid 41097708)
44. Stenzl A, Burger M, Fradet Y, et al. Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer. J Urol. 2010;184:1907-1913.
45. Grossman HB, Gomella L, Fradet Y, et al. PC B302/01 Study Group. A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer. J Urol. 2007;178:62-67. (Pubitemid 46908731)
46. Yoder BJ, Skacel M, Hedgepeth R, et al. Reflex UroVysion testing of bladder cancer surveillance patients with equivocal or negative urine cytology: a prospective study with focus on the natural history of anticipatory positive findings. Am J Clin Pathol. 2007;127:295-301. (Pubitemid 46797189)
47. Yoder BJ, Skacel M, Hedgepeth R, et al. Reflex UroVysion testing of bladder cancer surveillance patients with equivocal or negative urine cytology: a prospective study with focus on the natural history of anticipatory positive findings. Am J Clin Pathol. 2007;127:295-301. (Pubitemid 46797189)
48. Caraway NP, Katz RL. A review on the current state of urine cytology emphasizing the role of fluorescence in situ hybridization as an adjunct to diagnosis. Cancer Cytopathol. 2010;118:175-183.